Major depressive disorder appears frequently in discussions of ketamine therapy, though the strength of the supporting evidence differs considerably from indication to indication and it is worth being precise about where this one sits. The current position is that ketamine use for major depressive disorder is best described as strong evidence, and its regulatory status is off-label for iv ketamine. This page covers the mechanism as currently understood, the shape of the trial evidence, who the treatment is realistically appropriate for, how a course is structured, what it costs, and the questions worth putting to a clinician before starting.
Read against the United States market, the relevant question about a provider is not only whether they are licensed but whether their training covers both the psychiatric assessment and the physiological monitoring. Anyone comparing the United States programmes will find this decisive: a history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. Preparation before the first session matters for the same reason: people who know in advance what the dissociative period feels like generally find it far less alarming. Applied to the United States, the point is this: researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account.
What the research says about ketamine and Major depressive disorder
In the United States the same rule applies: a separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. If the neuroplasticity hypothesis is right, what happens between sessions is not an optional extra but part of how the treatment is meant to function. Patients researching the United States providers run into this constantly. Someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. It is the first thing to establish about any the United States programme.
The background that makes the United States listings interpretable is this. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
It is worth pausing on the underlying medicine before returning to the United States. Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
How a course is structured for this indication
That holds in the United States as it does everywhere: the gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. The induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. Nothing about the United States changes that. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. The United States listings on this page are organised so that this is checkable rather than assumed. For anyone weighing options in the United States, programmes differ enormously in how seriously they take the therapeutic work around the infusion, ranging from employed therapists to a photocopied worksheet.
Comparing clinics is difficult because the variables that matter are not the ones displayed on the website. Two facilities can charge similar prices and offer materially different care. The questions that separate them are who is physically present during the session and what their credential is, whether monitoring is continuous or intermittent, how the dose is determined and whether it is adjusted between sessions, what the plan is if a person does not respond after the induction course, whether psychiatric care is coordinated with an existing prescriber, and what integration support exists. Those answers can be obtained in one phone call, and the willingness to give them plainly is itself informative.
Who is realistically a candidate for treatment of Major depressive disorder
The phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. Advertising routinely blurs the line between approved esketamine and off-label generic ketamine, and the distinction carries real consequences for coverage. That is as true in the United States as anywhere else in the country.
Set aside the United States for a moment, because the general position comes first. Integration is the term the field uses for the work of making sense of what happened, and it is the element most likely to be missing from a purely procedural clinic. The neuroplasticity hypothesis implies that the days following a session may be unusually receptive to therapeutic change, which suggests that pairing sessions with structured psychological support is not an upsell but a plausible way to use the window. Programmes vary enormously in how seriously they take this: some employ therapists and build integration sessions into the protocol, others hand over a worksheet, and some do nothing at all. Asking directly what integration support is included, and whether it costs extra, separates the two models quickly.
Risks, side effects and screening
The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. It is worth carrying that into every conversation with a the United States provider. That holds in the United States as it does everywhere: a programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed.
What follows applies to the United States and to every other market, and it is the part worth reading slowly. Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
What treatment costs and what insurance does
The headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow. That is as true in the United States as anywhere else in the country. The practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable. Using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. It is worth carrying that into every conversation with a the United States provider.
What a properly run programme looks like from the inside
Ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. Nothing about the United States changes that. The part worth underlining is that the information gap in the United States is not about whether ketamine treatment exists locally but about how to tell two local programmes apart. Continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. The useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. Response, where it occurs, is frequently not permanent, and many people move onto maintenance sessions spaced every two to six weeks. Whether a programme is led by someone trained in sedation or someone trained in mood disorders changes what gets emphasised and what gets assumed.
The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
Esketamine, sold as Spravato, holds FDA approval for treatment-resistant depression in adults alongside an oral antidepressant, which puts it in a different regulatory category from generic infusions. The United States listings on this page are organised so that this is checkable rather than assumed. A clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. In the United States the same rule applies: a driver is mandatory, and across six sessions in three weeks that means arranging somebody else's time repeatedly rather than once. Nausea is common enough that many programmes give an antiemetic pre-emptively rather than waiting to see.
Making a decision about Major depressive disorder treatment
Anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. For anyone weighing options in the United States, each session occupies roughly two hours on site once administration, monitoring and recovery are counted, which is longer than most people budget for. Ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. Patients researching the United States providers run into this constantly. Dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending. Integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics.
Anyone reading this while unwell deserves a straight answer rather than a sales pitch, and the straight answer is that this is a real option for a specific group of people, with real limits that are worth knowing first.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.